var data={"title":"Eosinophilic fasciitis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Eosinophilic fasciitis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/contributors\" class=\"contributor contributor_credentials\">Simon M Helfgott, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/contributors\" class=\"contributor contributor_credentials\">John Varga, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/contributors\" class=\"contributor contributor_credentials\">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/contributors\" class=\"contributor contributor_credentials\">Monica Ramirez Curtis, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 13, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eosinophilic fasciitis (EF, also called Shulman syndrome) is an uncommon disorder of unknown etiology and poorly understood pathogenesis [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/1\" class=\"abstract_t\">1</a>]. EF is characterized in its early phase by limb or trunk erythema and edema and later by collagenous thickening of the subcutaneous fascia. Eosinophilia is a prominent laboratory finding in the early phase, although not always present in active early cases and less prominent in later stages [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/2\" class=\"abstract_t\">2</a>].</p><p>This topic will review the clinical manifestations, pathology, diagnosis, differential diagnosis, and treatment of EF. The approach to the patient with eosinophilia, and other major causes of eosinophilia are discussed separately. (See <a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">&quot;Approach to the patient with unexplained eosinophilia&quot;</a> and <a href=\"topic.htm?path=eosinophil-biology-and-causes-of-eosinophilia\" class=\"medical medical_review\">&quot;Eosinophil biology and causes of eosinophilia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3161796482\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The etiology of eosinophilic fasciitis (EF) is unknown. The following have been suggested as possible triggers or factors associated with EF [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/3\" class=\"abstract_t\">3</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Strenuous exercise [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/1\" class=\"abstract_t\">1</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initiation of hemodialysis [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/4\" class=\"abstract_t\">4</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infection with <em>Borrelia burgdorferi</em> [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/5-7\" class=\"abstract_t\">5-7</a>] </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Physical factors such as radiation therapy and burns</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Graft-versus-host disease (GVHD)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exposure to certain medications including statins, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, <a href=\"topic.htm?path=ramipril-drug-information\" class=\"drug drug_general\">ramipril</a>, and subcutaneous heparin [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/8\" class=\"abstract_t\">8</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Autoimmune diseases including thyroid disease [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/9-13\" class=\"abstract_t\">9-13</a>], primary biliary cirrhosis, systemic lupus erythematosus, and Sj&ouml;gren&rsquo;s syndrome</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hematologic disorders (see <a href=\"#H2114086153\" class=\"local\">'Association with hematologic disorders'</a> below)</p><p/><p>However, most cases of EF are not associated with these factors and are considered idiopathic.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Eosinophilic fasciitis (EF) is characterized by symmetrical induration of the skin and deeper perimuscular fascial planes [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/14,15\" class=\"abstract_t\">14,15</a>]. The onset is typically acute, and findings include erythema, swelling, and induration of the extremities that is accompanied by a peripheral blood eosinophilia [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/16\" class=\"abstract_t\">16</a>]. A subacute course may also occur. The thickening and hide-bound quality of the affected skin is somewhat similar to that seen with the scleroderma-spectrum disorders.</p><p class=\"headingAnchor\" id=\"H2655476694\"><span class=\"h2\">Symptoms and signs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following features can be observed in patients with EF:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Skin involvement</strong> &ndash; Nearly all patients with EF have clinically apparent symmetrical skin involvement, although unilateral skin disease can occur. There is a temporal evolution of skin findings. Initially, there may be marked, non-pitting edema of the skin. With progression of the disease, the swelling resolves and is replaced by symmetrical induration with puckering that gives the skin the texture of orange peel (peau d&rsquo;orange). While the initial edematous phase may be indistinguishable from early sclerodermatous skin changes, the irregular, woody, peau d&rsquo;orange texture of EF is distinct from the smooth, shiny skin surface seen in patients with systemic sclerosis or localized scleroderma (<a href=\"image.htm?imageKey=RHEUM%2F65829\" class=\"graphic graphic_picture graphicRef65829 \">picture 1</a>). Skin involvement most commonly occurs on the extremities, neck, and trunk. Sclerodactyly, the hallmark of systemic sclerosis, is absent in EF. Moreover, the skin of the hands and feet is generally spared.</p><p/><p class=\"bulletIndent1\">Elevation of an affected limb, which reduces the distending venous pressure, causes visible indentation along the course of the superficial veins (<a href=\"image.htm?imageKey=RHEUM%2F98466\" class=\"graphic graphic_picture graphicRef98466 \">picture 2</a>). This physical finding, referred to as the &ldquo;groove sign,&rdquo; is probably due to the relative sparing of the epidermis and superficial dermis by the fibrotic process coupled with the relative immobility of the connective tissue around the remainder of the veins. Thus, the superficial layers of skin can bow inward as the peripheral venous pressure falls.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Arthritis</strong> &ndash; Inflammatory arthritis occurs in a substantial minority of patients with EF. In one study of 52 patients, 40 percent had arthritis [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17\" class=\"abstract_t\">17</a>]. The arthritis tends to involve joints in the areas adjacent to fasciitis. Limited joint mobility may be the result of thickening and loss of pliability of overlying skin and fascia. Joint contractures may develop, sometimes occurring in the absence of typical skin involvement [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/18\" class=\"abstract_t\">18</a>]. In the series of 52 patients cited earlier [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17\" class=\"abstract_t\">17</a>], 56 percent had flexion contractures of the joints.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Myalgias and myositis </strong>&ndash;<strong> </strong>Muscle pain and muscle weakness are common symptoms in EF [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/19\" class=\"abstract_t\">19</a>]. Deep skin and fascial involvement merging into perimyositis may occur. However, inflammatory myositis is uncommon.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Neuropathies </strong>&ndash;<strong> </strong>Cranial and peripheral neuropathies have occurred more often than would be expected by chance. Carpal tunnel syndrome has been a commonly described peripheral neuropathy in association with EF [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17,20\" class=\"abstract_t\">17,20</a>], occurring in 12 of 52 patients (23 percent) in one series [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17\" class=\"abstract_t\">17</a>]. In one case, electromyography (EMG) and nerve conduction studies characterized a peripheral neuropathy of the lower extremities as being due to mononeuritis multiplex [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Visceral involvement</strong> &ndash; Visceral involvement is almost always absent in patients with EF [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17\" class=\"abstract_t\">17</a>], with a few exceptions. A few cases of pleural effusions [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/22\" class=\"abstract_t\">22</a>], pericarditis [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/23\" class=\"abstract_t\">23</a>], and renal involvement [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/24\" class=\"abstract_t\">24</a>] have been described.</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The majority of patients with EF have a peripheral blood eosinophilia [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17\" class=\"abstract_t\">17</a>]. Peripheral eosinophilia is transient and does not correlate with disease severity. Over 50 percent of patients have an elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as well as a polyclonal hypergammaglobulinemia [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17,25\" class=\"abstract_t\">17,25</a>]. Serum antinuclear antibodies have not been reported to be present in EF with any consistency [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/15\" class=\"abstract_t\">15</a>]. Serum levels of creatine kinase (CK) are typically normal, even in patients with myalgia.</p><p class=\"headingAnchor\" id=\"H2114086153\"><span class=\"h2\">Association with hematologic disorders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hematologic disorders can be associated with EF in up to 10 percent of patients and can be the presenting manifestation [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17\" class=\"abstract_t\">17</a>]. Hematologic abnormalities that have been described in association with EF include [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17,26-36\" class=\"abstract_t\">17,26-36</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aplastic anemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acquired amegakaryocytic thrombocytopenia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Myeloproliferative disorders</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Myelodysplastic syndromes</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymphoma</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymphocytic and eosinophilic leukemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple myeloma</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Paroxysmal nocturnal hemoglobinuria</p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H3047858240\"><span class=\"h2\">Overall approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of eosinophilic fasciitis (EF) is suspected in patients presenting with erythema, swelling, and induration of the extremities that is accompanied by peripheral eosinophilia. Skin changes typically spare the hands and feet, and evidence of systemic involvement is usually absent. The absence of a history of Raynaud phenomenon helps to distinguish EF from systemic sclerosis. In most cases, the diagnosis of EF is confirmed with a full skin-to-muscle biopsy. We obtain magnetic resonance imaging (MRI) of the affected area when the biopsy is nondiagnostic or cannot be obtained. In atypical cases (eg, fasciitis without skin changes), MRI may also be useful for guiding the location of a biopsy. In light of the association of EF with hematologic disorders, we also carefully review the complete blood count to determine whether further hematologic investigations are warranted.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Skin biopsy for EF requires an elliptical full thickness incisional biopsy of skin and subcutaneous tissues down to the muscle surface. Although there is no pathognomonic finding of EF on biopsy, the finding of compatible changes in the deep dermis and fascia at any point in the disease course is helpful in ruling out systemic sclerosis and other scleroderma-like disorders.</p><p>Early in the course of the disease, the deep fascia and lower subcutis are edematous and are infiltrated with lymphocytes, plasma cells, histiocytes, and eosinophils; these features are generally associated with peripheral eosinophilia. Eosinophil infiltrates are present in the majority of patients but may also be absent [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/8\" class=\"abstract_t\">8</a>]. These structures become thickened and sclerotic as the illness progresses, with disappearance of inflammatory cell infiltrates (<a href=\"image.htm?imageKey=RHEUM%2F68370\" class=\"graphic graphic_picture graphicRef68370 \">picture 3</a>) [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/37\" class=\"abstract_t\">37</a>].</p><p>Infiltrating eosinophils in the fascia degranulate locally, resulting in release and tissue accumulation of cationic granule proteins with toxic and potentially fibrogenic properties (<a href=\"image.htm?imageKey=RHEUM%2F76113\" class=\"graphic graphic_picture graphicRef76113 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/38\" class=\"abstract_t\">38</a>]. Mast cells and their degranulation product, histamine, have been found in affected tissue as well, and elevated circulating levels of histamine have been noted in some patients [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/39\" class=\"abstract_t\">39</a>].</p><p>Histologic abnormalities are also frequently found in the subjacent muscle. Thickening and inflammation of varying severity occurs in the epimysium, in the perimysium, in the endomysium, and, to a lesser degree, within muscle fibers. This was illustrated in a study of 15 patients with EF who had muscle biopsies that were compared with biopsies from 94 postmortem controls [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/40\" class=\"abstract_t\">40</a>]. All 15 had some degree of inflammation of the epi-, peri-, or endomysium or of muscle fibers. With routine histologic studies, the inflammation in EF in or around muscles could not be distinguished from that seen in other idiopathic inflammatory myopathies, such as polymyositis or dermatomyositis.</p><p class=\"headingAnchor\" id=\"H359650145\"><span class=\"h3\">Magnetic resonance imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Findings on MRI are helpful to confirm fascial inflammation [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/41-43\" class=\"abstract_t\">41-43</a>]. Increased T2 signal in the subcutaneous and deep fascia and enhancement of these structures on fat-suppressed T1 images after gadolinium administration have been noted [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/18,41-46\" class=\"abstract_t\">18,41-46</a>]. If MRI is not possible or is contraindicated, other imaging modalities that can be used include ultrasound and 18F-fluorodeoxyglucose positron emission <span class=\"nowrap\">tomography/computed</span> tomography <span class=\"nowrap\">(FDG-PET/CT)</span> [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/47,48\" class=\"abstract_t\">47,48</a>]. We prefer ultrasound because of its ease of administration and lower cost compared with nuclear medicine testing.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of other disorders including localized and systemic sclerosis as well as exposures to certain chemicals (tryptophan- or 5-hydroxytryptophan-containing products) should be considered in the differential diagnosis of eosinophilic fasciitis (EF).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Localized scleroderma</strong> &ndash; Localized forms of scleroderma include morphea and linear scleroderma. Unlike EF, localized scleroderma generally has a slowly progressive course and is not associated with significant eosinophilia. (See <a href=\"topic.htm?path=overview-and-classification-of-scleroderma-disorders#H2\" class=\"medical medical_review\">&quot;Overview and classification of scleroderma disorders&quot;, section on 'Localized scleroderma'</a> and <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-morphea-localized-scleroderma-in-adults\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Systemic sclerosis</strong> &ndash; Skin changes associated with systemic sclerosis may be difficult to distinguish from those of EF. The absence of the Raynaud phenomenon favors a diagnosis of EF, since the overwhelming majority of patients with limited and diffuse cutaneous forms of systemic sclerosis have or develop Raynaud phenomenon at or near the time of the earliest skin changes. Nailfold capillaries are typically normal in EF, while dilated capillary loops and avascular areas observed by capillaroscopy are suggestive of systemic sclerosis [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/49\" class=\"abstract_t\">49</a>]. Unlike systemic sclerosis, the fingers, feet, and face are spared in EF. Internal organ involvement (eg, pulmonary fibrosis, pulmonary hypertension, renal crisis) is frequent in systemic sclerosis but typically absent in EF. In contrast to systemic sclerosis, EF is not associated with serum antinuclear antibodies or systemic sclerosis-specific autoantibodies. (See <a href=\"topic.htm?path=diagnosis-and-differential-diagnosis-of-systemic-sclerosis-scleroderma-in-adults\" class=\"medical medical_review\">&quot;Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults&quot;</a> and <a href=\"topic.htm?path=overview-of-the-clinical-manifestations-of-systemic-sclerosis-scleroderma-in-adults\" class=\"medical medical_review\">&quot;Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Scleroderma-like disorders</strong> &ndash; Skin thickening and decreased pliability similar to that seen with scleroderma and EF may occur in the following scleroderma-like disorders. (See <a href=\"topic.htm?path=diagnosis-and-differential-diagnosis-of-systemic-sclerosis-scleroderma-in-adults#H7\" class=\"medical medical_review\">&quot;Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults&quot;, section on 'Causes of scleroderma-like skin changes'</a>.):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Nephrogenic systemic fibrosis</strong> &ndash; Among patients with advanced renal failure (dialysis-dependent or estimated glomerular filtration rate less than 15 <span class=\"nowrap\">mL/min),</span> the administration of gadolinium and perhaps erythropoietin may be associated with nephrogenic systemic fibrosis (previously called nephrogenic fibrosing dermopathy) that most often occurs in dialysis patients. The clinical manifestations of this apparently novel syndrome resemble EF but are distinguished by frequent involvement of the hands and feet and the absence of eosinophilia and eosinophilic tissue infiltration. (See <a href=\"topic.htm?path=nephrogenic-systemic-fibrosis-nephrogenic-fibrosing-dermopathy-in-advanced-renal-failure\" class=\"medical medical_review\">&quot;Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Scleromyxedema</strong> &ndash; Scleromyxedema is an idiopathic disorder that may occur alone or in association with malignancies. Skin thickening is due to the deposition of an amorphous mucinous material in the dermis [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/50\" class=\"abstract_t\">50</a>]. The presence of waxy, yellow-red papules and a serum monoclonal gammopathy are characteristic features. (See <a href=\"topic.htm?path=cutaneous-manifestations-of-internal-malignancy#H28414818\" class=\"medical medical_review\">&quot;Cutaneous manifestations of internal malignancy&quot;, section on 'Scleromyxedema'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Scleredema</strong> &ndash; Diffuse skin induration without evidence of inflammation on biopsy is typical of scleredema. These skin changes may occur in patients with diabetes, typically those with longstanding insulin-treated disease. Scleredema may occur in the absence of associated diabetes mellitus. Associated plasma cell disorder and a monoclonal gammopathy have been described. (See <a href=\"topic.htm?path=scleredema\" class=\"medical medical_review\">&quot;Scleredema&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Eosinophilia and skin thickening</strong> &ndash; When significant peripheral blood eosinophilia and skin or fascial thickening are both present, the differential diagnosis is more limited; among the diseases to be considered are the following:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Eosinophilia myalgia syndrome</strong> &ndash; The pathology of skin and subcutaneous tissue in eosinophilia-myalgia syndrome (EMS), a condition associated with use of L-tryptophan, cannot be differentiated from EF. Most cases of EMS resulted from exposure to a contaminant of the dietary supplement L-tryptophan used principally to treat insomnia. The illness occurred in an epidemic form in 1989, and subsequent sporadic cases have been rare [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/51\" class=\"abstract_t\">51</a>]. A related supplement, 5-hydroxytryptophan, has also been suggested as a cause. Myalgias, often severe, are seen in EMS and remain a criterion for classification, whereas they are infrequent and mild in patients with EF. Nonpitting edema that evolves into induration with a peau d'orange appearance in EMS is similar to that seen with EF [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/16\" class=\"abstract_t\">16</a>]. Visceral involvement, such as pneumonitis and neuropathy, may occur in patients with EMS, whereas these are uncommon in EF. (See <a href=\"topic.htm?path=risk-factors-for-and-possible-causes-of-systemic-sclerosis-scleroderma#H14\" class=\"medical medical_review\">&quot;Risk factors for and possible causes of systemic sclerosis (scleroderma)&quot;, section on 'L-tryptophan'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Toxic oil syndrome</strong> &ndash; Adulterated rapeseed oil was associated with an epidemic outbreak in the 1980s in Spain. The illness was characterized by symptoms of dyspnea, myalgia, and arthralgia; physical findings of limb edema, chronic scleroderma-like skin changes, livedo reticularis, neuropathy, and joint contractures [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/52-54\" class=\"abstract_t\">52-54</a>]. Other clinical features included pulmonary infiltrates, prominent eosinophilia, and elevation of serum creatine kinase (CK) [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/52-54\" class=\"abstract_t\">52-54</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Graft-versus-host disease</strong> &ndash; Skin fibrosis is a common manifestation of chronic graft-versus-host-disease (GVHD). Both morphea-like, localized induration and eosinophilic fasciitis have been described [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/55\" class=\"abstract_t\">55</a>]. (See <a href=\"topic.htm?path=cutaneous-manifestations-of-graft-versus-host-disease-gvhd#H877766\" class=\"medical medical_review\">&quot;Cutaneous manifestations of graft-versus-host disease (GVHD)&quot;, section on 'Sclerotic manifestations'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H26\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Systemic glucocorticoids are the mainstay of treatment of eosinophilic fasciitis (EF). Patients who do not respond to initial therapy with glucocorticoids or who have relapses require additional therapy. Patients with an associated hematologic disorder should be treated for the underlying disease. </p><p class=\"headingAnchor\" id=\"H2500764324\"><span class=\"h2\">Initial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No randomized trials have evaluated therapies for EF, and the best approach to treatment remains unclear. Our approach is to treat initially with systemic glucocorticoids, usually starting at doses equivalent to <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 1 <span class=\"nowrap\">mg/kg</span> per day [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17,56,57\" class=\"abstract_t\">17,56,57</a>]. There is often a rapid resolution of the peripheral blood eosinophilia and normalization of the erythrocyte sedimentation rate (ESR). Doses are reduced as the affected skin softens, which can take from weeks to months. If symptoms and signs of EF do not improve and eosinophilia persists, higher doses of glucocorticoids may be necessary.</p><p>All patients treated with high-dose glucocorticoids are at risk for glucocorticoid-induced osteoporosis. Thus, patients initiating treatment courses of EF are potential candidates for antiresorptive therapy to prevent bone loss. The prevention and treatment of glucocorticoid-induced osteoporosis are discussed separately (see <a href=\"topic.htm?path=prevention-and-treatment-of-glucocorticoid-induced-osteoporosis\" class=\"medical medical_review\">&quot;Prevention and treatment of glucocorticoid-induced osteoporosis&quot;</a>). Also, patients on high-dose glucocorticoid therapy are at increased risk for opportunistic infection. Prophylaxis against <em>Pneumocystic jirovecii</em>&nbsp;is thus often indicated for patients treated with high-dose <span class=\"nowrap\">glucocorticoids&nbsp;and/or&nbsp;other</span> immunosuppressive agents. (See <a href=\"topic.htm?path=treatment-and-prevention-of-pneumocystis-pneumonia-in-hiv-uninfected-patients#H9\" class=\"medical medical_review\">&quot;Treatment and prevention of Pneumocystis pneumonia in HIV-uninfected patients&quot;, section on 'Prophylaxis'</a>.)</p><p class=\"headingAnchor\" id=\"H2392072307\"><span class=\"h2\">Subsequent therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Relapses may occur, and many patients do not respond to glucocorticoids [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17,56,58\" class=\"abstract_t\">17,56,58</a>]; thus, in some patients, other immunosuppressive or immunomodulatory agents are required to obtain a therapeutic response <span class=\"nowrap\">and/or</span> act as glucocorticoid-sparing agents. In patients with no evidence of a response to <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> at doses of up to 1.5 <span class=\"nowrap\">mg/kg/day</span> given for three months, we use low-dose <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (15 to 25 mg once weekly), using the dosing employed in rheumatoid arthritis. The usual duration of therapy once remission is achieved is four to six months, depending upon the clinical response. (See <a href=\"topic.htm?path=use-of-methotrexate-in-the-treatment-of-rheumatoid-arthritis\" class=\"medical medical_review\">&quot;Use of methotrexate in the treatment of rheumatoid arthritis&quot;</a>.)</p><p>Alternatives to <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> include <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> or <a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">hydroxychloroquine</a>, although there are limited data supporting the use of either agent [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17\" class=\"abstract_t\">17</a>]. A two- to four-month trial of one or the other of these agents should be sufficient to assess the clinical response.</p><p class=\"headingAnchor\" id=\"H2100910058\"><span class=\"h2\">Other interventions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The successful use of other therapies is largely based on anecdotal reports and case series. Some of these interventions include <a href=\"topic.htm?path=sulfasalazine-drug-information\" class=\"drug drug_general\">sulfasalazine</a>, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a>, <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a>, <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a>, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> A, D-penicillamine, Psoralen plus ultraviolet A (PUVA) photochemotherapy, and antithymocyte globulin [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17,25,57,59-65\" class=\"abstract_t\">17,25,57,59-65</a>]. Consideration for these agents should be reserved for those patients with refractory disease that is unresponsive to more traditional second- and third-line therapies.</p><p>Surgical release of joint contractures in combination with glucocorticoid therapy has been used by some authors [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/66\" class=\"abstract_t\">66</a>]. Others have resorted to surgical fasciectomy in patients resistant to glucocorticoids [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/67\" class=\"abstract_t\">67</a>]. Surgical release may also be necessary for some patients with chronic carpal tunnel syndrome that does not respond to glucocorticoids [<a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/20\" class=\"abstract_t\">20</a>].</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eosinophilic fasciitis (EF, also called Shulman syndrome) is an uncommon disorder of unknown etiology and poorly understood pathogenesis. The onset is typically acute, and findings include erythema, swelling, and induration of the extremities that is accompanied by a peripheral blood eosinophilia. (See <a href=\"#H2\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The thickening and hide-bound quality of the affected skin is somewhat similar to that seen with the scleroderma-spectrum disorders; however, sclerodactyly, the hallmark of systemic sclerosis, is absent in EF. Moreover, the skin of the hands and feet is generally spared. Elevation of an affected limb, which reduces the distending venous pressure, causes visible indentation (the groove sign) along the course of the superficial veins (<a href=\"image.htm?imageKey=RHEUM%2F98466\" class=\"graphic graphic_picture graphicRef98466 \">picture 2</a>). (See <a href=\"#H2655476694\" class=\"local\">'Symptoms and signs'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The majority of EF patients have a peripheral blood eosinophilia. Peripheral eosinophilia is transient and does not correlate with disease severity. Over 50 percent of patients have an elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as well as a polyclonal hypergammaglobulinemia. (See <a href=\"#H10\" class=\"local\">'Laboratory findings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hematologic disorders can be associated with EF in up to 10 percent of patients and can be the presenting manifestation. (See <a href=\"#H2114086153\" class=\"local\">'Association with hematologic disorders'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of EF is suspected in patients presenting with erythema, swelling, and induration of the extremities that is accompanied by peripheral eosinophilia. Skin changes typically spare the hands and feet, and evidence of systemic involvement is usually absent. In most cases, the diagnosis of EF is confirmed with a full skin-to-muscle biopsy. We obtain magnetic resonance imaging (MRI) of the affected area when the biopsy is nondiagnostic or cannot be obtained. In atypical cases (eg, fasciitis without skin changes), MRI may also be useful for guiding the location of a biopsy. (See <a href=\"#H3047858240\" class=\"local\">'Overall approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis includes localized and systemic sclerosis; scleroderma-like disorders such as nephrogenic systemic fibrosis, scleromyxedema, and scleredema; eosinophilia myalgia syndrome (EMS), toxic oil syndrome; and graft-versus-host disease (GVHD). (See <a href=\"#H16\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For all patients with EF, we suggest initial management with systemic glucocorticoids, usually starting at doses equivalent to <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 1 <span class=\"nowrap\">mg/kg</span> per day (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Doses are reduced as the affected skin softens, which can take from weeks to months. If symptoms and signs of EF do not improve and eosinophilia persists, higher doses of glucocorticoids may be necessary. Patients with an associated hematologic disorder should be treated for the underlying disease. (See <a href=\"#H2500764324\" class=\"local\">'Initial therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with no evidence of a response to <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> at doses of up to 1.5 <span class=\"nowrap\">mg/kg/day</span> given for three months, we suggest treatment with low-dose <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (15 to 25 mg once weekly) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). The usual duration of therapy once remission is achieved is four to six months, depending upon the clinical response. (See <a href=\"#H2392072307\" class=\"local\">'Subsequent therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alternatives to <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> include <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> or <a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">hydroxychloroquine</a>, although there are limited data supporting the use of either agent. A two- to four-month trial of one or the other of these agents should be sufficient to assess the clinical response. (See <a href=\"#H2392072307\" class=\"local\">'Subsequent therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The successful use of other therapies is largely based on anecdotal reports and case series. Some of these interventions include <a href=\"topic.htm?path=sulfasalazine-drug-information\" class=\"drug drug_general\">sulfasalazine</a>, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a>, <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>, intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-drug-information\" class=\"drug drug_general\">immune globulin</a>, <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a>, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> A, D-penicillamine, Psoralen plus ultraviolet A (PUVA) photochemotherapy, and antithymocyte globulin. Consideration for these agents should be reserved for those patients with refractory disease that is unresponsive to more traditional second- and third-line therapies. Rarely, surgical interventions have been used in patients resistant to glucocorticoids. (See <a href=\"#H2100910058\" class=\"local\">'Other interventions'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/1\" class=\"nounderline abstract_t\">Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 1975; 88:70.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/2\" class=\"nounderline abstract_t\">Falanga V, Medsger TA Jr. Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. J Am Acad Dermatol 1987; 17:648.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/3\" class=\"nounderline abstract_t\">Pinal-Fernandez I, Selva-O' Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 2014; 13:379.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/4\" class=\"nounderline abstract_t\">Florell SR, Egan CA, Gregory MC, et al. Eosinophilic fasciitis occurring four weeks after the onset of dialysis in a renal failure patient. J Cutan Med Surg 2001; 5:33.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/5\" class=\"nounderline abstract_t\">Granter SR, Barnhill RL, Duray PH. Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection. Am J Dermatopathol 1996; 18:465.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/6\" class=\"nounderline abstract_t\">Hashimoto Y, Takahashi H, Matsuo S, et al. Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Dermatology 1996; 192:136.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/7\" class=\"nounderline abstract_t\">Mosconi S, Streit M, Br&ouml;nimann M, Braathen L. Eosinophilic fasciitis (Shulman syndrome). Dermatology 2002; 205:204.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/8\" class=\"nounderline abstract_t\">Long H, Zhang G, Wang L, Lu Q. Eosinophilic Skin Diseases: A Comprehensive Review. Clin Rev Allergy Immunol 2016; 50:189.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/9\" class=\"nounderline abstract_t\">Bachmeyer C, Monge M, Dh&ocirc;te R, et al. Eosinophilic fasciitis following idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Hashimoto's disease. Dermatology 1999; 199:282.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/10\" class=\"nounderline abstract_t\">Farrell AM, Ross JS, Bunker CB. Eosinophilic fasciitis associated with autoimmune thyroid disease and myelodysplasia treated with pulsed methylprednisolone and antihistamines. Br J Dermatol 1999; 140:1185.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/11\" class=\"nounderline abstract_t\">Imren S, T&uuml;z&uuml;ner N, Yazici H. Eosinophilic fasciitis with thyroid disease. Clin Exp Rheumatol 1988; 6:96.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/12\" class=\"nounderline abstract_t\">Boiesen M, Keiding LM, Thomsen K. Eosinophilic fasciitis. Report of a case with features of other autoimmune disease. Dermatologica 1983; 167:142.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/13\" class=\"nounderline abstract_t\">Smiley AM, Husain M, Indenbaum S. Eosinophilic fasciitis in association with thyroid disease: a report of three cases. J Rheumatol 1980; 7:871.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/14\" class=\"nounderline abstract_t\">Rodnan GP, DiBartolomeo A, Medsger TA Jr. Proceedings: Eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome. Arthritis Rheum 1975; 18:525.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/15\" class=\"nounderline abstract_t\">Doyle JA, Ginsburg WW. Eosinophilic fasciitis. Med Clin North Am 1989; 73:1157.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/16\" class=\"nounderline abstract_t\">Varga J, Griffin R, Newman JH, Jimenez SA. Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use. J Rheumatol 1991; 18:259.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/17\" class=\"nounderline abstract_t\">Lakhanpal S, Ginsburg WW, Michet CJ, et al. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1988; 17:221.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/18\" class=\"nounderline abstract_t\">Huppke P, Wilken B, Brockmann K, et al. Eosinophilic fasciitis leading to painless contractures. Eur J Pediatr 2002; 161:528.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/19\" class=\"nounderline abstract_t\">Nassonova VA, Ivanova MM, Akhnazarova VD, et al. Eosinophilic fasciitis. Review and report of six cases. Scand J Rheumatol 1979; 8:225.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/20\" class=\"nounderline abstract_t\">Jones HR Jr, Beetham WP Jr, Silverman ML, Margles SW. Eosinophilic fasciitis and the carpal tunnel syndrome. J Neurol Neurosurg Psychiatry 1986; 49:324.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/21\" class=\"nounderline abstract_t\">Moriguchi M, Terai C, Kuroki S, et al. Eosinophilic fasciitis complicated with peripheral polyneuropathy. Intern Med 1998; 37:417.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/22\" class=\"nounderline abstract_t\">Killen JW, Swift GL, White RJ. Eosinophilic fasciitis with pulmonary and pleural involvement. Postgrad Med J 2000; 76:36.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/23\" class=\"nounderline abstract_t\">Rizzo S. Eosinophilic pleuropericarditis and fasciitis. A new case. Monaldi Arch Chest Dis 2002; 57:311.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/24\" class=\"nounderline abstract_t\">Kirschstein M, Helmchen U, Jensen R, et al. Kidney involvement in a 17-year-old boy with eosinophilic fasciitis. Clin Nephrol 1999; 52:183.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/25\" class=\"nounderline abstract_t\">Lebeaux D, S&egrave;ne D. Eosinophilic fasciitis (Shulman disease). Best Pract Res Clin Rheumatol 2012; 26:449.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/26\" class=\"nounderline abstract_t\">Doyle JA, Connolly SM, Hoagland HC. Hematologic disease in scleroderma syndromes. Acta Derm Venereol 1985; 65:521.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/27\" class=\"nounderline abstract_t\">Hoffman R, Dainiak N, Sibrack L, et al. Antibody-mediated aplastic anemia and diffuse fasciitis. N Engl J Med 1979; 300:718.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/28\" class=\"nounderline abstract_t\">Littlejohn GO, Keystone EC. Eosinophilic fasciitis and aplastic anaemia. J Rheumatol 1980; 7:730.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/29\" class=\"nounderline abstract_t\">Chaudhary UB, Eberwine SF, Hege KM. Acquired amegakaryocytic thrombocytopenia purpura and eosinophilic fasciitis: a long relapsing and remitting course. Am J Hematol 2004; 75:146.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/30\" class=\"nounderline abstract_t\">Khanna D, Verity A, Grossman JM. Eosinophilic fasciitis with multiple myeloma: a new haematological association. Ann Rheum Dis 2002; 61:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/31\" class=\"nounderline abstract_t\">Jacob SE, Lodha R, Cohen JJ, et al. Paraneoplastic eosinophilic fasciitis: a case report. Rheumatol Int 2003; 23:262.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/32\" class=\"nounderline abstract_t\">Haddad H, Sundaram S, Magro C, Gergis U. Eosinophilic fasciitis as a paraneoplastic syndrome, a case report and review of the literature. Hematol Oncol Stem Cell Ther 2014; 7:90.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/33\" class=\"nounderline abstract_t\">Ferguson JS, Bosworth J, Min T, et al. Eosinophilic fasciitis associated with hypereosinophilia, abnormal bone-marrow karyotype and inversion of chromosome 5. Clin Exp Dermatol 2014; 39:150.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/34\" class=\"nounderline abstract_t\">de Masson A, Bouaziz JD, Peffault de Latour R, et al. Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature. Medicine (Baltimore) 2013; 92:69.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/35\" class=\"nounderline abstract_t\">Naschitz JE, Misselevich I, Rosner I, et al. Lymph-node-based malignant lymphoma and reactive lymphadenopathy in eosinophilic fasciitis. Am J Med Sci 1999; 318:343.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/36\" class=\"nounderline abstract_t\">Eklund KK, Anttila P, Leirisalo-Repo M. Eosinophilic fasciitis, myositis and arthritis as early manifestations of peripheral T-cell lymphoma. Scand J Rheumatol 2003; 32:376.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/37\" class=\"nounderline abstract_t\">Barnes L, Rodnan GP, Medsger TA, Short D. Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol 1979; 96:493.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/38\" class=\"nounderline abstract_t\">Fredens K, Dybdahl H, Dahl R, Baandrup U. Extracellular deposit of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage. APMIS 1988; 96:711.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/39\" class=\"nounderline abstract_t\">Falanga V, Soter NA, Kerdel FA. Increased plasma histamine level in eosinophilic fasciitis. Arch Dermatol 1989; 125:805.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/40\" class=\"nounderline abstract_t\">Huang KW, Chen XH. Pathology of eosinophilic fasciitis and its relation to polymyositis. Can J Neurol Sci 1987; 14:632.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/41\" class=\"nounderline abstract_t\">Moulton SJ, Kransdorf MJ, Ginsburg WW, et al. Eosinophilic fasciitis: spectrum of MRI findings. AJR Am J Roentgenol 2005; 184:975.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/42\" class=\"nounderline abstract_t\">De Clerck LS, Degryse HR, Wouters E, et al. Magnetic resonance imaging in the evaluation of patients with eosinophilic fasciitis. J Rheumatol 1989; 16:1270.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/43\" class=\"nounderline abstract_t\">Ronneberger M, Janka R, Schett G, Manger B. Can MRI substitute for biopsy in eosinophilic fasciitis? Ann Rheum Dis 2009; 68:1651.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/44\" class=\"nounderline abstract_t\">Nakajima H, Fujiwara S, Shinoda K, Ohsawa N. Magnetic resonance imaging and serum aldolase concentration in eosinophilic fasciitis. Intern Med 1997; 36:654.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/45\" class=\"nounderline abstract_t\">al-Shaikh A, Freeman C, Avruch L, McKendry RJ. Use of magnetic resonance imaging in diagnosing eosinophilic fasciitis. Report of two cases. Arthritis Rheum 1994; 37:1602.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/46\" class=\"nounderline abstract_t\">Baumann F, Br&uuml;hlmann P, Andreisek G, et al. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol 2005; 184:169.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/47\" class=\"nounderline abstract_t\">Kim HJ, Lee SW, Kim GJ, Lee JH. Usefulness of FDG PET/CT in the diagnosis of eosinophilic fasciitis. Clin Nucl Med 2014; 39:801.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/48\" class=\"nounderline abstract_t\">Kissin EY, Garg A, Grayson PC, et al. Ultrasound assessment of subcutaneous compressibility: a potential adjunctive diagnostic tool in eosinophilic fasciitis. J Clin Rheumatol 2013; 19:382.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/49\" class=\"nounderline abstract_t\">Herson S, Brechignac S, Piette JC, et al. Capillary microscopy during eosinophilic fasciitis in 15 patients: distinction from systemic scleroderma. Am J Med 1990; 88:598.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/50\" class=\"nounderline abstract_t\">Mori Y, Kahari VM, Varga J. Scleroderma-like cutaneous syndromes. Curr Rheumatol Rep 2002; 4:113.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/51\" class=\"nounderline abstract_t\">Allen JA, Peterson A, Sufit R, et al. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum 2011; 63:3633.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/52\" class=\"nounderline abstract_t\">Alonso-Ruiz A, Zea-Mendoza AC, Salazar-Vallinas JM, et al. Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma. Semin Arthritis Rheum 1986; 15:200.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/53\" class=\"nounderline abstract_t\">Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1995; 7:560.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/54\" class=\"nounderline abstract_t\">Posada de la Paz M, Philen RM, Borda AI. Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev 2001; 23:231.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/55\" class=\"nounderline abstract_t\">Schaffer JV, McNiff JM, Seropian S, et al. Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. J Am Acad Dermatol 2005; 53:591.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/56\" class=\"nounderline abstract_t\">Lebeaux D, Franc&egrave;s C, Barete S, et al. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford) 2012; 51:557.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/57\" class=\"nounderline abstract_t\">Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol 2008; 47:29.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/58\" class=\"nounderline abstract_t\">Endo Y, Tamura A, Matsushima Y, et al. Eosinophilic fasciitis: report of two cases and a systematic review of the literature dealing with clinical variables that predict outcome. Clin Rheumatol 2007; 26:1445.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/59\" class=\"nounderline abstract_t\">Schiener R, Behrens-Williams SC, Gottl&ouml;ber P, et al. Eosinophilic fasciitis treated with psoralen-ultraviolet A bath photochemotherapy. Br J Dermatol 2000; 142:804.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/60\" class=\"nounderline abstract_t\">Pimenta S, Bernardes M, Bernardo A, et al. Intravenous immune globulins to treat eosinophilic fasciitis: a case report. Joint Bone Spine 2009; 76:572.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/61\" class=\"nounderline abstract_t\">Bonnotte B, Chauffert B, Caillot D, et al. Successful treatment with antithymocyte globulin and cyclosporin A of a severe aplastic anaemia associated with an eosinophilic fasciitis. Br J Rheumatol 1998; 37:1358.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/62\" class=\"nounderline abstract_t\">Caspi D, Fishel R, Varon M, et al. Multisystem presentation of eosinophilic fasciitis. Rheumatol Rehabil 1982; 21:218.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/63\" class=\"nounderline abstract_t\">Jones AC, Doherty M. Eosinophilic fasciitis with late onset arthritis responsive to sulfasalazine. J Rheumatol 1993; 20:750.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/64\" class=\"nounderline abstract_t\">Khanna D, Agrawal H, Clements PJ. Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology (Oxford) 2010; 49:1184.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/65\" class=\"nounderline abstract_t\">Scheinberg M, Hamerschlak N, Kutner JM, et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol 2006; 24:65.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/66\" class=\"nounderline abstract_t\">Suzuki G, Itoh Y, Horiuchi Y. Surgical management of eosinophilic fasciitis of the upper extremity. J Hand Surg Br 1997; 22:405.</a></li><li><a href=\"https://www.uptodate.com/contents/eosinophilic-fasciitis/abstract/67\" class=\"nounderline abstract_t\">Neumeister MW, Robertson GA. Therapeutic fasciectomy for eosinophilic fasciitis. Ann Plast Surg 1998; 41:208.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7547 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H27\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H3161796482\" id=\"outline-link-H3161796482\">ETIOLOGY</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLINICAL FEATURES</a><ul><li><a href=\"#H2655476694\" id=\"outline-link-H2655476694\">Symptoms and signs</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Laboratory findings</a></li><li><a href=\"#H2114086153\" id=\"outline-link-H2114086153\">Association with hematologic disorders</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">DIAGNOSIS</a><ul><li><a href=\"#H3047858240\" id=\"outline-link-H3047858240\">Overall approach</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">- Biopsy</a></li><li><a href=\"#H359650145\" id=\"outline-link-H359650145\">- Magnetic resonance imaging</a></li></ul></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">TREATMENT</a><ul><li><a href=\"#H2500764324\" id=\"outline-link-H2500764324\">Initial therapy</a></li><li><a href=\"#H2392072307\" id=\"outline-link-H2392072307\">Subsequent therapy</a></li><li><a href=\"#H2100910058\" id=\"outline-link-H2100910058\">Other interventions</a></li></ul></li><li><a href=\"#H27\" id=\"outline-link-H27\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"RHEUM/7547|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=RHEUM/65829\" class=\"graphic graphic_picture\">- Skin in eosinophilic fasciitis</a></li><li><a href=\"image.htm?imageKey=RHEUM/98466\" class=\"graphic graphic_picture\">- Eosinophilic fasciitis groove sign</a></li><li><a href=\"image.htm?imageKey=RHEUM/68370\" class=\"graphic graphic_picture\">- Eosinophilic fasciitis biopsy 1</a></li><li><a href=\"image.htm?imageKey=RHEUM/76113\" class=\"graphic graphic_picture\">- Eosinophilic fasciitis biopsy 2</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">Approach to the patient with unexplained eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-manifestations-of-graft-versus-host-disease-gvhd\" class=\"medical medical_review\">Cutaneous manifestations of graft-versus-host disease (GVHD)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-manifestations-of-internal-malignancy\" class=\"medical medical_review\">Cutaneous manifestations of internal malignancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-differential-diagnosis-of-systemic-sclerosis-scleroderma-in-adults\" class=\"medical medical_review\">Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=eosinophil-biology-and-causes-of-eosinophilia\" class=\"medical medical_review\">Eosinophil biology and causes of eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nephrogenic-systemic-fibrosis-nephrogenic-fibrosing-dermopathy-in-advanced-renal-failure\" class=\"medical medical_review\">Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-and-classification-of-scleroderma-disorders\" class=\"medical medical_review\">Overview and classification of scleroderma disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-clinical-manifestations-of-systemic-sclerosis-scleroderma-in-adults\" class=\"medical medical_review\">Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-morphea-localized-scleroderma-in-adults\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-treatment-of-glucocorticoid-induced-osteoporosis\" class=\"medical medical_review\">Prevention and treatment of glucocorticoid-induced osteoporosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risk-factors-for-and-possible-causes-of-systemic-sclerosis-scleroderma\" class=\"medical medical_review\">Risk factors for and possible causes of systemic sclerosis (scleroderma)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=scleredema\" class=\"medical medical_review\">Scleredema</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-pneumocystis-pneumonia-in-hiv-uninfected-patients\" class=\"medical medical_review\">Treatment and prevention of Pneumocystis pneumonia in HIV-uninfected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-methotrexate-in-the-treatment-of-rheumatoid-arthritis\" class=\"medical medical_review\">Use of methotrexate in the treatment of rheumatoid arthritis</a></li></ul></div></div>","javascript":null}